Q-omics provides the consensus-scored UPB1 profile across patient tissues and cancer cell-line models. UPB1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, UPB1 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, UPB1 RNA expression shows 14,280 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRP, and TGCT as cancer lineages where UPB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UPB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UPB1 survival associations across molecular data types. UPB1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UPB1 RNA expression–survival associations across cancer types. High UPB1 expression shows favorable associations in HNSC, KIRC, LUAD, KIRP, LIHC and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for UPB1 RNA expression.
This table summarizes UPB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UPB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UPB1 shows lower tumor expression in KIRP, THCA, KICH, LUSC and LUAD and higher tumor expression in KIRC. The KIRP box plot shows higher UPB1 RNA expression in normal versus tumor tissue (log2 FC = −4.362, t-test p < 0.001).
This table shows molecular features associated with UPB1 in patient tissues and cancer cell lines. In patient samples, UPB1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, UPB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
